Literature DB >> 14688322

Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.

Kristina Fleischer1, Burkhard Schmidt, Wolfgang Kastenmüller, Dirk H Busch, Ingo Drexler, Gerd Sutter, Michael Heike, Christian Peschel, Helga Bernhard.   

Abstract

Immunization with heat shock proteins (hsp) isolated from cancer cells has been shown to induce a protective antitumor response. The mechanism of hsp-dependent cellular immunity has been attributed to a variety of immunological activities mediated by hsp. Hsp have been shown to bind antigenic peptides, trim the bound peptides by intrinsic enzymatic activity, improve endocytosis of the chaperoned peptides by APCs, and enhance the ability of APCs to stimulate peptide-specific T cells. We have investigated the potential capacity of hsp70 and gp96 to function as a mediator for Ag-specific CTL stimulation in an in vitro model for human melanoma. Repetitive stimulation of PBLs by autologous DCs loaded with melanoma-derived hsp did not increase the frequency of T cells directed against immunodominant peptides of melanoma-associated Ags Melan-A and tyrosinase. In contrast, repeated T cell stimulation with peptide-pulsed DCs enhanced the number of peptide-specific T cells, allowing HLA/peptide multimer-guided T cell cloning. We succeeded in demonstrating that the established HLA-A2-restricted CTL clones recognized HLA-A2(+) APCs exogenously loaded with the respective melanoma peptide as well as melanoma cells processing and presenting these peptides in the context of HLA-A2. We were not able to show that these melanoma-reactive CTL clones were stimulated by autologous dendritic cells pulsed with melanoma-derived hsp. These results are discussed with respect to various models for proving the role of hsp in T cell stimulation and to recent findings that part of the immunological antitumor activities reported for hsp are independent of the chaperoned peptides.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14688322     DOI: 10.4049/jimmunol.172.1.162

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Visualization of antigen-specific human cytotoxic T lymphocytes labeled with superparamagnetic iron-oxide particles.

Authors:  Ambros J Beer; Konstantin Holzapfel; Juliana Neudorfer; Guido Piontek; Marcus Settles; Holger Krönig; Christian Peschel; Jürgen Schlegel; Ernst J Rummeny; Helga Bernhard
Journal:  Eur Radiol       Date:  2008-02-20       Impact factor: 5.315

2.  De novo generation of specific human IgGs by in vitro immunization using autologous proteins containing immunogenic p-nitrophenylalanine.

Authors:  Yue Tong; Xu Fang; Hong Tian; Shengwei Zhong; Liang Jin; Xiangdong Gao; Wenbing Yao
Journal:  MAbs       Date:  2018-12-22       Impact factor: 5.857

3.  Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes.

Authors:  Sheena N Smith; Daniel Sommermeyer; Kurt H Piepenbrink; Sydney J Blevins; Helga Bernhard; Wolfgang Uckert; Brian M Baker; David M Kranz
Journal:  J Mol Biol       Date:  2013-08-14       Impact factor: 5.469

Review 4.  The messenger and the message: gp96 (GRP94)-peptide interactions in cellular immunity.

Authors:  Christopher V Nicchitta; Deanna M Carrick; Julie C Baker-Lepain
Journal:  Cell Stress Chaperones       Date:  2004       Impact factor: 3.667

5.  Molecular mimics of the tumour antigen MUC1.

Authors:  Tharappel C James; Ursula Bond
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

6.  A novel method to identify and characterise peptide mimotopes of heat shock protein 70-associated antigens.

Authors:  Derek G Doherty; Ursula Bond; Blanca Arnaiz; Laura Madrigal-Estebas; Stephen Todryk; Tharappel C James
Journal:  J Immune Based Ther Vaccines       Date:  2006-04-08

7.  NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

Authors:  Daniel Sommermeyer; Heinke Conrad; Holger Krönig; Haike Gelfort; Helga Bernhard; Wolfgang Uckert
Journal:  Int J Cancer       Date:  2012-09-14       Impact factor: 7.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.